TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22784349

Group type: EXPERIMENTAL
Intervention: Manasamitra Vataka tablets (100 mg twice daily for 30 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Manasamitra Vataka tablets (100 mg twice daily for 30 days) + Shirodhara (first 7 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Clonazepam 0.75 mg daily in divided dose for 30 days
Number of subjects: 72
Study: 20409337

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream for 6 weeks (superficial basal cell carcinoma) or 12 weeks (nodular basal cell carcinoma)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Excisional surgery
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 500
Study: 17826977

Group type: EXPERIMENTAL
Intervention: CDE (cyclophosphamide/doxorubicin/etoposide)
Number of subjects: 203

Group type: COMPARATOR
Intervention: CP (carboplatin/paclitaxel)
Number of subjects: 203
Study: 16086364

Group type: COMPARATOR
Intervention: Fexofenadine HCl 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyzine HCl 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12697867

Group type: COMPARATOR
Intervention: High-dose chlorambucil (15 mg/m2/d) plus prednisone (100 mg/d) for 5 days (HD-CHL-P; arm A)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: High-dose chlorambucil (15 mg/m2/d) plus prednisone (100 mg/d) for 5 days plus epirubicin 60 mg/m2 intravenous on day 1 (arm B)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Interferon alfa (IFNalpha-2a; 3 MU, three times weekly) for 12 months
Number of subjects: 170

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 170
Study: 10933079

Group type: EXPERIMENTAL
Intervention: Interactive seminar for physicians focused on communication and teaching skills for asthma management.
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Children seen by treatment group physicians.
Number of subjects: 637

Group type: COMPARATOR
Intervention: Control group physicians (not specified intervention).
Number of subjects: 637
Study: 8879895

Group type: EXPERIMENTAL
Intervention: IFN‐alpha daily for 4 weeks and then intermittently for 20 weeks (total dose, 348 MU)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: IFN‐alpha daily for 2 weeks and then intermittently for 22 weeks (total dose, 480 MU)
Number of subjects: 127

Group type: COMPARATOR
Intervention: IFN‐alpha daily for 8 weeks (total dose, 336 MU)
Number of subjects: 127
Study: 1995974

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 6661605

Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 62

Group type: COMPARATOR
Intervention: Pseudo-ECT
Number of subjects: 62
Study: 30768414

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combined cognitive‐behavioral and fluoxetine treatment (COMB)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 439
Study: 28356125

Group type: EXPERIMENTAL
Intervention: Group music therapy offered three times per week in a community centre with a focus on songwriting.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention during the study period).
Number of subjects: 30
Study: 27693439

Group type: EXPERIMENTAL
Intervention: Chlorhexidine umbilical cord care (10 mL of a 4% chlorhexidine solution applied once per day until 3 days after cord drop)
Number of subjects: 39679

Group type: COMPARATOR
Intervention: Dry cord care (control)
Number of subjects: 39679
Study: 24118830

Group type: EXPERIMENTAL
Intervention: Fluvastatin (Lescol®) 40-80 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (Omacor®) high-dose (2-4 g)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (Omacor®) low-dose (1 g)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (Omacor®) low-dose + fluvastatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (Omacor®) high-dose + fluvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no active drug)
Number of subjects: 60
Study: 22144725

Group type: EXPERIMENTAL
Intervention: Early mobilization out of bed after 52 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delayed mobilization out of bed after seven days
Number of subjects: 50
Study: 19171735

Group type: EXPERIMENTAL
Intervention: A1C level
Number of subjects: 0
Study: 17206633

Group type: EXPERIMENTAL
Intervention: Natalizumab (300 mg) plus infliximab (5 mg/kg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Infliximab (5 mg/kg) alone
Number of subjects: 79
Study: 16295704

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Stress Management (SM)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Stress Management (SM) with adequate adherence
Number of subjects: 332
Study: 12476481

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.05% cream plus UVB radiation with penicillin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.05% cream plus UVB radiation without penicillin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral psoralen plus ultraviolet A (PUVA) therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Systemic retinoids therapy
Number of subjects: 60
Study: 10378438

Group type: EXPERIMENTAL
Intervention: Intentional group (informed about novel sounds and asked to memorize)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Incidental group (not informed about novel sounds)
Number of subjects: 32
Study: 8527622

Group type: EXPERIMENTAL
Intervention: ranitidine bismuth citrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 1793881

Group type: EXPERIMENTAL
Intervention: midazolam 0.3 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: thiopental 5 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: diazepam 0.4 mg/kg
Number of subjects: 30
Study: 6891235

Group type: EXPERIMENTAL
Intervention: Eucebral‐N (80 mg etofylline and 100 mg cyclandelate) administered for 4 weeks
Number of subjects: 0
Study: 30760337

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard Surgical Dressing (SSD)
Number of subjects: 73
Study: 28098165

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) and oxymetazoline (OXY)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) and placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Placebo and oxymetazoline (OXY)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo and placebo
Number of subjects: 240
Study: 26048168

Group type: EXPERIMENTAL
Intervention: TAU+SCT
Number of subjects: 538

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 538
Study: 23219538

Group type: EXPERIMENTAL
Intervention: Epididymectomy with concurrent administration of hyaluronic acid and carboxymethylcellulose (group 1)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Epididymectomy only (group 2)
Number of subjects: 43
Study: 21544020

Group type: EXPERIMENTAL
Intervention: P6 stimulation
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 134
Study: 18470667

Group type: EXPERIMENTAL
Intervention: Alendronate monotherapy (5 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vitamin K(2) (45 mg/day) plus alendronate (5 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Alendronate monotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of vitamin K(2) and alendronate
Number of subjects: 48
Study: 16541981

Group type: EXPERIMENTAL
Intervention: Therapeutic practice
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sensorimotor intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 12671780

Group type: EXPERIMENTAL
Intervention: Educational and counseling intervention (3 individual sessions by trained nurses)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (standard of care)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Educational and counseling intervention
Number of subjects: 244
Study: 11093992

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg x kg.min(‐1) at induction, then 0.2 microg x kg x min(‐1))
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fentanyl (3 microg/kg)
Number of subjects: 34
Study: 9368164

Group type: EXPERIMENTAL
Intervention: 10‐0 nylon suture
Number of subjects: 100

Group type: COMPARATOR
Intervention: 9‐0 nylon suture
Number of subjects: 100
Study: 1403077

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250mg every 12 hours for 10 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: Amoxicillin 50mg/kg/day in three divided doses for 10 days
Number of subjects: 55
Study: 3896885

Group type: EXPERIMENTAL
Intervention: nifedipine (30 mg/D)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 31908254

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 1.5 mg/kg/h infusion until 2 h after surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment with 0.9% saline (equal volume to lidocaine group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 60
Study: 28958701

Group type: EXPERIMENTAL
Intervention: High dose (HD) influenza vaccine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard dose (SD) influenza vaccine
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Influenza infection post-vaccination
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV) seropositivity
Number of subjects: 106
Study: 27322715

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMX) during high-dose methotrexate (HDMTX)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMX) during low-dose methotrexate (40 mg/m)
Number of subjects: 424
Study: 24708676

Group type: EXPERIMENTAL
Intervention: Intensive day-camp intervention (6-week multi-component day camp including increased physical activity, healthy diet, and health education) followed by 46 weeks of family-based habitual intervention.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard care arm (two weekly hours of physical activity training for six weeks).
Number of subjects: 115
Study: 23218157

Group type: EXPERIMENTAL
Intervention: Adjunctive ziprasidone 60-80 mg
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Adjunctive ziprasidone 20-40 mg
Number of subjects: 680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study: 20932302

Group type: COMPARATOR
Intervention: Video podcast
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Live lecture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multiple choice questions
Number of subjects: 100
Study: 18418571

Group type: EXPERIMENTAL
Intervention: SSD-coated ETT (SSD-ETT, n=23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard non-coated ETT (St-ETT, n=23; control group)
Number of subjects: 46
Study: 18573983

Group type: EXPERIMENTAL
Intervention: Fee per sealant treatment
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Education in evidence-based practice
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Fee plus education
Number of subjects: 2833

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2833
Study: 15042614

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (60 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 11399692

Group type: EXPERIMENTAL
Intervention: Initial diagnosis of COPD based on hypothetical case presentation
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Diagnosis of COPD after spirometry
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Diagnosis of COPD after oral steroid trial
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Request for spirometry after initial presentation
Number of subjects: 192
Study: 9240873

Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (12.3 mg/l iron)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Non-fortified formula (1.4 mg/l iron)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 406
Study: 8494130

Group type: EXPERIMENTAL
Intervention: Leg wrapping with elasticated Esmarch bandages
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Leg elevation alone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (neither leg elevation nor wrapping)
Number of subjects: 97
Study: 3327673

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Minoxidil
Number of subjects: 118
Study: 30064264

Group type: EXPERIMENTAL
Intervention: Geriatric interdisciplinary home rehabilitation (n=106)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Conventional geriatric care and rehabilitation (n=93)
Number of subjects: 205
Study: 29946728

Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg orally once daily for 21 days followed by 7 days off in 28-day cycles (n=278)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo (n=138)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 26745852

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 1776
Study: 24974317

Group type: EXPERIMENTAL
Intervention: SES-related risk
Number of subjects: 627
Study: 22824596

Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nepafenac
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 20639271

Group type: EXPERIMENTAL
Intervention: Avonex 1 x 30 microg/week (IFN‐30)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Avonex 1 x 60 microg/week (IFN‐60)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17998225

Group type: EXPERIMENTAL
Intervention: 300,000 IU intramuscular vitamin D2 injection
Number of subjects: 9440
Study: 16311455

Group type: EXPERIMENTAL
Intervention: Tympanic membrane displacement (TMD) measurements using the Marchbanks measurement system analyser
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Invasive measurements of ICP
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group of volunteers
Number of subjects: 225
Study: 12487015

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 142
Study: 9788030

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 42
Study: 7808602

Group type: EXPERIMENTAL
Intervention: 0.1 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 0.2 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 0.4 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All dose groups (0.1 mg, 0.2 mg, 0.4 mg)
Number of subjects: 53
Study: 2684309

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 82

Group type: COMPARATOR
Intervention: Methotrexate-cyclosporine
Number of subjects: 82
Study: 4712485

Group type: EXPERIMENTAL
Intervention: Auditory perceptual tasks
Number of subjects: 0
Study: 31563589

Group type: EXPERIMENTAL
Intervention: Acute c‐ICA stenting
Number of subjects: 24

Group type: COMPARATOR
Intervention: No stenting
Number of subjects: 24
Study: 30633414

Group type: EXPERIMENTAL
Intervention: Extent of dissection (higher number of dissected facial nerve branches)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Postoperative follow-up (scar appearance and substance loss)
Number of subjects: 148
Study: 28647161

Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway
Number of subjects: 506

Group type: COMPARATOR
Intervention: Conventional pathway
Number of subjects: 506
Study: 25865175

Group type: EXPERIMENTAL
Intervention: Frequent self-weighing (daily or several times per week)
Number of subjects: 583
Study: 23332012

Group type: EXPERIMENTAL
Intervention: CD8(+)CD38(+)HLA-DR(+) T-cell activation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: soluble vascular cell adhesion molecule (sVCAM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: tumour necrosis factor-α receptor-I (TNFR-I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: fibrinogen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Age and CD8(+)CD38(+)HLA-DR(+) percentage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: sVCAM concentration
Number of subjects: 60
Study: 21406510

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 12507

Group type: COMPARATOR
Intervention: As-needed LABA
Number of subjects: 12507
Study: 18506620

Group type: EXPERIMENTAL
Intervention: docetaxel/capecitabine (TX)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: doxorubicin/cyclophosphamide (AC) followed by paclitaxel (T)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/doxorubicin/cyclophosphamide (FAC)
Number of subjects: 122
Study: 17204967

Group type: EXPERIMENTAL
Intervention: Micronutrient sprinkles (MMN) containing iron 12.5 mg + folic acid 150 microg + zinc 5 mg + vitamins A, C and D3
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Iron/folate sprinkles (iron 12.5 mg + folic acid 150 microg)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 15133373

Group type: EXPERIMENTAL
Intervention: Relaxation response (RR) training
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cardiac education
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study: 15171476

Group type: EXPERIMENTAL
Intervention: Measurement of blood volume changes during hemodialysis using an online blood volume monitor (Hemoscan)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: deltaBV/UF ratio
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: deltaBV/UF ratio of less than 2.6%/L
Number of subjects: 12
Study: 11369149

Group type: EXPERIMENTAL
Intervention: Self-treatment group (n=123)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Active control group (n=122)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Both groups (self-treatment and active control)
Number of subjects: 245
Study: 9260599

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg orally twice a day
Number of subjects: 406

Group type: COMPARATOR
Intervention: Ondansetron suppository 16 mg once daily
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 406
Study: 8317686

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% and prilocaine 2% in a 1:1 ratio
Number of subjects: 60
Study: 3551127

Group type: EXPERIMENTAL
Intervention: Labetalol (Trandate; Allen & Hanburys)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dihydralazine (Nepresol; Ciba)
Number of subjects: 20
Study: 29596123

Group type: EXPERIMENTAL
Intervention: Fast-track recovery protocol (FT), n = 32
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional protocol (CON), n = 30
Number of subjects: 62
Study: 27836132

Group type: EXPERIMENTAL
Intervention: Intraprocedural Thrombotic Events (IPTEs)
Number of subjects: 6591

Group type: COMPARATOR
Intervention: Control (no IPTE)
Number of subjects: 6591
Study: 24754606

Group type: EXPERIMENTAL
Intervention: Mobile epidural analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mobile epidural analgesia
Number of subjects: 0
Study: 23572341

Group type: EXPERIMENTAL
Intervention: 30% inhaled xenon for 24 h combined with 72 h of moderate systemic hypothermia
Number of subjects: 14
Study: 20529340

Group type: EXPERIMENTAL
Intervention: Exercise and diet intervention
Number of subjects: 597
Study: 19066383

Group type: EXPERIMENTAL
Intervention: Lottery incentive program
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Deposit contract
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (monthly weigh-ins)
Number of subjects: 57
Study: 16368312

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥ 30 kg/m2)
Number of subjects: 2082
Study: 14651695

Group type: EXPERIMENTAL
Intervention: Swallowing training (30 minutes per day, 6 days per week for 8 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 61
Study: 10552108

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8893656

Group type: EXPERIMENTAL
Intervention: Benzodiazepine (mini doses)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1379970

Group type: EXPERIMENTAL
Intervention: Org 10172
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 6391442

Group type: EXPERIMENTAL
Intervention: Topical betaxolol hydrochloride 0.5% every 12 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical betaxolol hydrochloride 0.5% every 12 hours with oral acetazolamide 500 mg every 12 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide 500 mg every 12 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide 500 mg every 12 hours with topical betaxolol
Number of subjects: 0
Study: 31733455

Group type: EXPERIMENTAL
Intervention: S-Adenosyl-Methionine (SAMe) 3,200 mg/day
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65